Inhibitor Therapeutics (INTI)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.98 mm	2.98 mm	2.98 mm	2.98 mm	2.98 mm	2.98 mm
Cash burn (monthly)	253.75 k	283.47 k	247.07 k	299.65 k	253.75 k	283.47 k
Cash used (since last report)	581.53 k	649.64 k	566.23 k	686.72 k	581.53 k	649.64 k
Cash remaining	2.40 mm	2.33 mm	2.41 mm	2.29 mm	2.40 mm	2.33 mm
Runway (months of cash)	9.4	8.2	9.8	7.6	9.4	8.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q1 2023

INTI institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0.00	0.00
Total shares	0.00	0.00
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

INTI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Dec 24	Michelle Yanez	Common Stock	Gift	Acquire G	No	No	0	250,000	0.00	1,146,271
2 Dec 24	Mcnulty James A	Common Stock	Gift	Acquire G	No	No	0	1,000,000	0.00	1,946,135

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.